PT - JOURNAL ARTICLE AU - IGOR KISS AU - ZBYNEK BORTLICEK AU - BOHUSLAV MELICHAR AU - ALEXANDR POPRACH AU - JANA HALAMKOVA AU - ROSTISLAV VYZULA AU - LADISLAV DUSEK AU - TOMAS BUCHLER TI - Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma DP - 2014 Feb 01 TA - Anticancer Research PG - 949--954 VI - 34 IP - 2 4099 - http://ar.iiarjournals.org/content/34/2/949.short 4100 - http://ar.iiarjournals.org/content/34/2/949.full SO - Anticancer Res2014 Feb 01; 34 AB - The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 2.5%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.